Pluri Overview
Pluri creates cell-based products for commercial use and aims to promote global wellbeing and sustainability. The company's technology platform, a patented and validated 3D cell expansion system, advances novel cell-based solutions for a range of initiatives, from medicine and climate change to food scarcity and animal cruelty. Pluri's method is accurate, scalable, cost effective, and consistent from batch to batch. Pluri currently operates in the field of regenerative medicine and food technology and aims to establish partnerships that leverage the company's 3D cell-based technology in additional industries that require effective, mass cell production.
Cumulative Funding Raised Over Time ($)
$20.0MApr 2019
$74.0MApr 2020
$104.0MFeb 2021
$119.0MJan 2017
$125.5MJan 2025
$155.5MOct 2016
Latest News
growth-positive
Plurilock Announces Insider Share Purchases
Plurilock Security Inc., a global cybersecurity systems integrator, announced that its executive team, Board of Directors, and other insiders, along with certain employees, have purchased approximately 531,000 common shares of the company on the open market. This move reflects confidence in Plurilocks long-term strategy and growth trajectory as it focuses on expanding its Critical Services business and pursuing new federal and commercial opportunities. The company is AI-native and trusted by Five-Eyes governments, NATO-aligned agencies, and Global 2000 enterprises. The insider purchases were made in accordance with applicable securities laws and the companys insider trading policy.
growth-positive
Pluri Subsidiary Coffeesai Partners with Mexico’s INCAFECH to Advance Cell-Based Coffee Manufacturing
Pluri Inc., a biotechnology company, announced a collaboration agreement through its subsidiary Coffeesai Ltd. with the Instituto del Café de Chiapas (INCAFECH) in Mexico. This partnership aims to advance cell-based coffee manufacturing in Chiapas, leveraging Pluris 3D cell expansion platform. The collaboration is designed to create shareholder value through potential non-dilutive revenues and recurring revenue streams. Pluris efforts in sustainable cell-based coffee products position Chiapas as a hub for innovation. The article suggests that while Pluri has potential, certain AI stocks might offer greater upside potential.
Partners
growth-positive
Pluri Subsidiary Coffeesai and Instituto del Café de Chiapas Announce Strategic Collaboration to Advance Cell-Based Coffee Manufacturing in Mexico
Pluri Inc., a biotechnology company, has announced a collaboration with the Instituto del Café de Chiapas (INCAFECH) to advance cell-based coffee manufacturing in Mexico. This partnership aims to establish a three-phase roadmap, including cell line development, pilot-scale biofarming, and commercial-scale manufacturing. The collaboration is expected to leverage Pluris proprietary 3D cell expansion platform to create sustainable coffee solutions resilient to climate change and market volatility. The initiative positions Chiapas as a hub for cell-based coffee innovation, blending biotechnology with local coffee traditions. The collaboration is structured to create shareholder value through potential non-dilutive revenues, recurring revenue streams, and market expansion.
PartnersProduct Stage
growth-negative
Plurilock Security Inc. Announces Sale of CloudCodes Assets to Scope Technologies Corp.
Plurilock Security Inc. has entered into an asset purchase agreement with Scope Technologies Corp. to sell certain assets of its CloudCodes business. The transaction, valued at $1,780,000, includes $100,000 in cash and 4,200,000 common shares of Scope. This divestiture aligns with Plurilocks strategic shift from serving SMEs to focusing on large enterprises and government clients. The transaction is expected to close around September 15, 2025, subject to customary conditions and regulatory approvals. Plurilock aims to streamline operations and concentrate on its Critical Services division, leveraging its AI-native cybersecurity solutions.
Acquisition
growth-positive
Plurilock Security Inc. Reports Second Quarter Fiscal 2025 Financial Results
Plurilock Security Inc., a global cybersecurity services and solutions provider, announced its financial results for Q2 2025, showing significant growth in revenue and professional services. The company reported a 159% increase in Critical Services revenue year-over-year and a 42% improvement in Adjusted EBITDA loss year-over-year. Total revenue for the quarter was $16.4 million, up from $14.3 million in the same period last year. The company is well-positioned to capture a meaningful share of the growing investment in cyber and defense sectors. Despite a one-time, lower-margin resale order impacting margins, the companys strategy of margin expansion remains strong.
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $133.4M |
| Last funding | $6.5M |
| Stage | Public |
| Rounds | 12 |
| Investors | 3 |
Team Members
7
Employees: 201-500
Web & Social Links
| Website | pluri-biotech.com/ |
Locations
Matam, Haifa, Israel
Photos & Videos
4 item(s)
Pluri Business
Business models
B2B
Product stage
Clinical Trial
Employees
201-500
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentTarget Customer
Agriculture & FoodCropsHealthcare & Life SciencesLife SciencesBiotechnologyPharmaceuticalsCore Technology
BiologicalsCellsTags (14)
orthopedicsinflammatory-diseasespulmonarybiological-therapyregenerative-medicinestem-cellscell-therapybioprocesscardiovascularpharmaceuticals3d-technologyspace-techpharma-companiespatientsGeographic Markets
AsiaEuropeUnited StatesUnited Arab EmiratesSouth KoreaPluri Financials
$133.4M
Total funding
Undisclosed
Capital raised
$6.5M
Last funding
Public
Funding stage
12
Total rounds
3
Investors
Cumulative Funding Raised Over Time ($)
$20.0MApr 2019
$74.0MApr 2020
$104.0MFeb 2021
$119.0MJan 2017
$125.5MJan 2025
$155.5MOct 2016
Private Equity Funding
PIPE
Jan 2025
$6.5M
Alejandro Weinstein (Lead)
PIPE
Feb 2021
$30M
Undisclosed Investor(s)
Debt Financing
Apr 2020
$54M
European Investment Bank (EIB)
PIPE
Apr 2019
$20M
PIPE
Jan 2017
$15M
Undisclosed Investor(s)
PIPE
Oct 2016
$30M
Non-Equity Funding
GrantEvent
Sep 2017
$8.7M
EU Horizon 2020
GrantEvent
May 2016
$3.3M
The Israeli Ministry of Economy
GrantEvent
Jun 2015
$2.9M
Office of the Chief Scientist
Public Offering / Exit
POEvent
Jun 2015
Undisclosed
POEvent
Dec 2010
Undisclosed
POEvent
Apr 2003
Undisclosed
Mergers & Acquisitions
MNAEvent
Jan 2025
$4.5M
Pluri Lifecycle
Cumulative Funding Raised Over Time
$20.0MApr 2019
$74.0MApr 2020
$104.0MFeb 2021
$119.0MJan 2017
$125.5MJan 2025
$155.5MOct 2016
All Events
PIPE
Jan 2025
$6.5M
Alejandro Weinstein (Lead)
PIPE
Feb 2021
$30M
Undisclosed Investor(s)
Debt Financing
Apr 2020
$54M
European Investment Bank (EIB)
PIPE
Apr 2019
$20M
PIPE
Jan 2017
$15M
Undisclosed Investor(s)
PIPE
Oct 2016
$30M
GrantEvent
Sep 2017
$8.7M
EU Horizon 2020
GrantEvent
May 2016
$3.3M
The Israeli Ministry of Economy
GrantEvent
Jun 2015
$2.9M
Office of the Chief Scientist
POEvent
Jun 2015
Undisclosed
POEvent
Dec 2010
Undisclosed
POEvent
Apr 2003
Undisclosed
MNAEvent
Jan 2025
$4.5M
Pluri News
107 articles
growth-positive
Plurilock Announces Insider Share Purchases
Plurilock Security Inc., a global cybersecurity systems integrator, announced that its executive team, Board of Directors, and other insiders, along with certain employees, have purchased approximately 531,000 common shares of the company on the open market. This move reflects confidence in Plurilocks long-term strategy and growth trajectory as it focuses on expanding its Critical Services business and pursuing new federal and commercial opportunities. The company is AI-native and trusted by Five-Eyes governments, NATO-aligned agencies, and Global 2000 enterprises. The insider purchases were made in accordance with applicable securities laws and the companys insider trading policy.
growth-positive
Pluri Subsidiary Coffeesai Partners with Mexico’s INCAFECH to Advance Cell-Based Coffee Manufacturing
Pluri Inc., a biotechnology company, announced a collaboration agreement through its subsidiary Coffeesai Ltd. with the Instituto del Café de Chiapas (INCAFECH) in Mexico. This partnership aims to advance cell-based coffee manufacturing in Chiapas, leveraging Pluris 3D cell expansion platform. The collaboration is designed to create shareholder value through potential non-dilutive revenues and recurring revenue streams. Pluris efforts in sustainable cell-based coffee products position Chiapas as a hub for innovation. The article suggests that while Pluri has potential, certain AI stocks might offer greater upside potential.
Partners
growth-positive
Pluri Subsidiary Coffeesai and Instituto del Café de Chiapas Announce Strategic Collaboration to Advance Cell-Based Coffee Manufacturing in Mexico
Pluri Inc., a biotechnology company, has announced a collaboration with the Instituto del Café de Chiapas (INCAFECH) to advance cell-based coffee manufacturing in Mexico. This partnership aims to establish a three-phase roadmap, including cell line development, pilot-scale biofarming, and commercial-scale manufacturing. The collaboration is expected to leverage Pluris proprietary 3D cell expansion platform to create sustainable coffee solutions resilient to climate change and market volatility. The initiative positions Chiapas as a hub for cell-based coffee innovation, blending biotechnology with local coffee traditions. The collaboration is structured to create shareholder value through potential non-dilutive revenues, recurring revenue streams, and market expansion.
PartnersProduct Stage
growth-negative
Plurilock Security Inc. Announces Sale of CloudCodes Assets to Scope Technologies Corp.
Plurilock Security Inc. has entered into an asset purchase agreement with Scope Technologies Corp. to sell certain assets of its CloudCodes business. The transaction, valued at $1,780,000, includes $100,000 in cash and 4,200,000 common shares of Scope. This divestiture aligns with Plurilocks strategic shift from serving SMEs to focusing on large enterprises and government clients. The transaction is expected to close around September 15, 2025, subject to customary conditions and regulatory approvals. Plurilock aims to streamline operations and concentrate on its Critical Services division, leveraging its AI-native cybersecurity solutions.
Acquisition
growth-positive
Plurilock Security Inc. Reports Second Quarter Fiscal 2025 Financial Results
Plurilock Security Inc., a global cybersecurity services and solutions provider, announced its financial results for Q2 2025, showing significant growth in revenue and professional services. The company reported a 159% increase in Critical Services revenue year-over-year and a 42% improvement in Adjusted EBITDA loss year-over-year. Total revenue for the quarter was $16.4 million, up from $14.3 million in the same period last year. The company is well-positioned to capture a meaningful share of the growing investment in cyber and defense sectors. Despite a one-time, lower-margin resale order impacting margins, the companys strategy of margin expansion remains strong.
growth-positive
Plurilock Announces Dates for Second Quarter 2025 Financial Results
Plurilock Security Inc., a global cybersecurity services provider, announced plans to release its Q2 2025 financial results on August 19, 2025. The company will host a webinar on August 20, 2025, led by CEO Ian L. Paterson and CFO Scott Meyers, to discuss the results and provide updates. Plurilock is an AI-native cybersecurity company trusted by governments and large enterprises to defend critical infrastructure. The webinar will be available on the companys website for stakeholders. The announcement is part of Plurilocks ongoing efforts to engage with investors and stakeholders.
growth-positive
Pluri CEO Issues Shareholder Letter Highlighting Strategic Growth, Innovation, and Global Market Expansion
Pluri Inc., a biotechnology company, reported a nearly 400% revenue growth in the first nine months of fiscal year 2025, driven by its CDMO and AgTech businesses. The company is making significant strides in the cultivated cacao and coffee markets, aiming to address global shortages due to climate change and rising demand. Pluris cell expansion platform allows for the production of pharmaceuticals, food products, and agricultural goods at a commercial scale. The company is aligning with an Israeli AgFoodTech company to develop cell-based cacao technology, supporting its vision of sustainable and vertically integrated solutions in the food industry.
Product StageCustomersPartners
growth-negative
Pluri: Fiscal Q3 Earnings Snapshot
Pluri Inc., a biotechnology company based in Haifa, Israel, reported a loss of $6.1 million for its fiscal third quarter. This translates to a loss of 94 cents per share. The company generated revenue of $427,000 during this period. The financial results indicate a growth-negative impact on the company. The article was generated using data from Zacks Investment Research and is available on their website.
growth-positive
Pluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFoodTech Company, Kokomodo Ltd.
Pluri Inc., a biotechnology company, has acquired a 71% stake in Kokomodo Ltd., an AgFoodTech company specializing in cultivated cacao production, for $4.5 million. This acquisition combines Pluris expertise in mass-scale cell production with Kokomodos cellular agriculture technology to produce climate-resilient cacao. Kokomodo will continue to operate independently under its current leadership while benefiting from Pluris resources. The acquisition aims to address climate change impacts on traditional cacao farming and meet the growing demand for sustainable cacao products. The global cacao market is projected to grow significantly, making this acquisition strategically beneficial for Pluri.
Acquisition
growth-positive
Pluri’s immune cell expansion technologies gain patents
Biotechnology company Pluri has announced the issuance of patents by the US Patent and Trademark Office and in Israel for its immune cell expansion technologies. The patents cover mucosal-associated invariant T (MAIT) cells, which are suitable for treating solid tumors and offer significant benefits over conventional T cells. Pluri has developed a method for large-scale culturing and activation of these cells using its 3D cell expansion bioreactors. The company believes its ability to scale production of MAIT cells, combined with its growing intellectual property portfolio, positions it for potential collaborations in immunotherapy. In 2023, Pluri signed a $4.2 million contract with the US National Institute of Allergy and Infectious Diseases and the US Department of Defense for developing cell therapy avoplacel.
Product StagePartners
growth-positive
Pluri Announces Expansion of Intellectual Property Portfolio with Two Granted Patents for 3D Expansion of Immune Cells in the United States and Israel
Pluri Inc., a biotechnology company, has strengthened its position in the field of cell-based cancer therapies by securing new patents for its MAIT cell expansion technologies. These patents, granted by the USPTO and mirrored in Israel, enhance Pluris intellectual property portfolio, which now includes over 250 patents. The companys proprietary platform enables large-scale production of MAIT cells, a promising avenue for cancer immunotherapy. With the recent FDA approval of related therapies, Pluri is well-positioned to advance its MAIT cell platform for treating solid tumors. The company aims to revolutionize cancer treatment and support other ventures in commercializing immunotherapy solutions.
Product Stage
growth-positive
Pluri Announces Exclusive Collaboration Agreement with Hemafund to Enhance Ukraine's Radiation Emergency Preparedness
Pluri Inc., a biotechnology company, has entered into a strategic collaboration with Hemafund Ltd., a Ukrainian umbilical cord blood bank, to address the urgent need for radiation countermeasures in Ukraine. This partnership aims to advance Pluris PLX-R18 cell therapy as a treatment for Hematopoietic Acute Radiation Syndrome (H-ARS) following nuclear radiation exposure. The collaboration will leverage Hemafunds infrastructure for biostorage and logistics to ensure rapid deployment of treatments. The agreement is initially set for three years, with potential for extension, and aims to generate over $100 million in value. The collaboration responds to recent escalations, including a Russian drone strike on the Chernobyl nuclear power plant.
Partners
growth-positive
Ever After Foods and Bühler Collaborate to Scale Cultivated Meat Production and Distribution
Ever After Foods, a foodtech innovator, has announced a strategic partnership with Bühler, a global leader in food equipment, to advance the development of commercial-scale cultivated meat production systems. This collaboration aims to address the challenges of feeding a growing global population by providing sustainable and scalable solutions for cultivated meat production. Ever After Foods proprietary edible packed-bed (EPB™) technology platform will be central to this effort, enabling efficient production at a lower scale than existing technologies. The partnership is expected to accelerate the deployment of these systems globally, supporting the transition of the protein system to meet future demands.
Partners
growth-negative
Pluri: Fiscal Q2 Earnings Snapshot
Pluri Inc., a biotechnology company based in Haifa, Israel, reported a financial loss of $3 million for its fiscal second quarter. The loss translates to 53 cents per share. During the same period, the company generated revenue of $185,000. This financial report indicates a challenging quarter for Pluri Inc., as the company continues to navigate the biotechnology sector. The data for this report was sourced from Zacks Investment Research and processed by Automated Insights.
growth-positive
Pluri Secures Additional $3.5 Million Investment from Major Shareholder at Premium to Market, Bringing Total Recent Financings to $10 Million
Pluri Inc., a biotechnology company, has announced a $3.5 million private placement investment from Merchant Adventure Fund, L.P., a long-term shareholder. This follows a recent $6.5 million investment by Alejandro Weinstein, bringing the total to $10 million in strategic investments over the past two weeks. The funds are intended to support Pluris growth and execution strategy as a leader in cell-based technology, with plans to expand into industries such as pharma, foodtech, and agtech. Additionally, Pluri is entering into an agreement to acquire Kokomodo Ltd., subject to shareholder approval, potentially entering the cacao market.
InvestmentAcquisition
growth-positive
Lab-Grown Chocolate: Israel's Pluri Acquires Kokomodo, Raises $6.5M
Pluri, an Israeli company specializing in cell-based technologies, has secured a $6.5 million investment from Alejandro Weinstein and acquired a 71% stake in Kokomodo, a company focused on cell-cultured cocoa. This acquisition, valued at $4.5 million, marks Pluris entry into the cell-based chocolate market. Pluri, originally a health tech company, has expanded into food and manufacturing, including cultivated meat and cell-based coffee. The investment aims to strengthen Pluris financial foundation and support its strategic growth in sustainable food technologies. The acquisition of Kokomodo is expected to enhance Pluris capabilities in the cultivated cacao sector, addressing the growing demand for sustainable food solutions.
InvestmentAcquisitionPartners
growth-positive
Pluri gets $6.5M investment from Alejandro Weinstein, enters cacao market
Pluri has announced a $6.5 million strategic private investment led by Alejandro Weinstein, who will join the companys board of directors. Concurrently, Pluri is acquiring a 71% stake in Kokomodo, an AgTech company specializing in cultivated cacao production, for $4.5 million payable in common shares. These moves are aimed at expanding Pluris leadership in sustainable food technologies and strengthening its strategic growth capabilities. The investment and acquisition are subject to customary regulatory and corporate approvals, including Pluri shareholder approval. The transactions are expected to close in the second quarter of 2025, with the investment proceeds intended for working capital and general corporate purposes.
InvestmentAcquisitionPartners
growth-positive
Pluri Secures $6.5 Million Strategic Investment at Premium to Market, Enters Cacao Market Through Acquisition
Pluri Inc., a biotechnology company, announced a $6.5 million strategic private investment led by global investor Alejandro Weinstein, who will join the companys Board of Directors. Concurrently, Pluri is acquiring a 71% stake in Kokomodo Ltd., an AgTech company specializing in cultivated cacao production, for $4.5 million payable in the companys common shares. These transactions aim to expand Pluris leadership in sustainable food technologies and strengthen its strategic growth and operational capabilities. The investment and acquisition are subject to shareholder approval and customary closing conditions, with the closing expected on or about January 31, 2025.
InvestmentAcquisition
growth-positive
Pluri Congratulates Mesoblast on FDA Approval of First Mesenchymal Stromal Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease
Pluri Inc., a leader in cell-based technologies, congratulates Mesoblast Ltd. on receiving FDA approval for the first MSC-based therapy for steroid-refractory acute graft-versus-host disease. This approval is a significant milestone in regenerative medicine, highlighting the potential of MSC therapies to transform healthcare by addressing root causes of diseases. Pluris CEO, Yaky Yanay, emphasizes the importance of this achievement for the entire field of cellular medicine and reiterates Pluris commitment to advancing MSC-based therapies. Pluris proprietary 3D cell-expansion technology positions it at the forefront of developing scalable cell-based therapies for unmet medical needs. The company remains dedicated to pioneering treatments that meet high standards of efficacy, safety, and accessibility.
growth-positive
Pluri Shortlisted for CDMO of the Year Award by Advanced Therapies Awards 2025
Pluri Inc., a biotechnology company, has been recognized for its PluriCDMO™ division, which was launched in January 2024. The division has been shortlisted for the CDMO of the Year Award by the Advanced Therapies Awards 2025. This recognition highlights Pluris achievements in offering scalable and mass-scale production solutions to innovative life science companies. The company has signed agreements with clients, leveraging its state-of-the-art GMP facilities and patented bioreactor system for 3D cell expansion. Pluris technology platform advances cell-based solutions across various fields, including regenerative medicine, foodtech, and agtech. The recognition is seen as a positive step towards supporting transformative therapies globally.
Partners
growth-positive
Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing
Investor Summit Group announced that presentations from the November 21, 2024 Winter Investor Summit Virtual Conference are now available for on-demand viewing. The event, aimed at advancing the MicroCap and SmallCap investment community, provides an opportunity for participants and those unable to attend to access valuable insights shared by industry experts. Investor Summit Group is dedicated to connecting investors with promising microcap and smallcap companies, offering a platform for discovering growth opportunities. The company emphasizes fostering a unique ecosystem where investors can engage with companies that have strong fundamentals and growth potential.
growth-positive
Pluri Evaluates Readiness for Mass Production of PLX-R18 for Acute Radiation Syndrome Amid Rising Nuclear Threat Concerns
Pluri Inc., a biotechnology company, is preparing to initiate mass production of its novel treatment, PLX-R18, in response to escalating global nuclear threats, particularly in Ukraine. PLX-R18 has shown promise in improving survival rates and recovery from hematopoietic complications of acute radiation syndrome (H-ARS) in preclinical studies. The U.S. FDA has approved an Investigational New Drug application for PLX-R18 and granted it Orphan Drug Designation. Pluri is evaluating its readiness to scale up production to meet potential global demand, leveraging its state-of-the-art manufacturing facility. This proactive approach aims to ensure global preparedness and support communities in need during emergencies.
growth-negative
Pluri First Quarter 2025 Earnings: US$1.08 loss per share (vs US$0.96 loss in 1Q 2024)
Pluri reported a net loss of $5.88 million, which represents a 19% increase in losses compared to the first quarter of 2024. The loss per share also deteriorated from $0.96 to $1.08. Despite these negative financial results, Pluris shares have risen by 20% over the past week. The article highlights that there are five warning signs associated with Pluri, two of which are significant. The analysis provided is based on historical data and analyst forecasts, and it does not constitute financial advice. Simply Wall St, the source of the article, does not hold any positions in the stocks mentioned.
growth-negative
Pluri: Fiscal Q1 Earnings Snapshot
Pluri Inc., a biotechnology company based in Haifa, Israel, reported a financial loss of $5.9 million for its fiscal first quarter. The loss translates to $1.08 per share. During the same period, the company generated revenue of $326,000. The report was generated using data from Zacks Investment Research and highlights the financial challenges faced by Pluri Inc. in the current fiscal period.
growth-positive
/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced...
BrainStorm Cell Therapeutics Inc. has signed a Memorandum of Understanding (MOU) with Pluri Inc. to manufacture NurOwn® for its planned Phase 3b trial in amyotrophic lateral sclerosis (ALS). This partnership will enable BrainStorm to transfer its manufacturing technology to Pluris facility in Israel, ensuring GMP-compliant production of NurOwn. The collaboration aims to meet the clinical supply requirements for the Phase 3b trial and explore future commercial distribution options. The trial will enroll approximately 200 participants and is designed to evaluate the efficacy of NurOwn in treating ALS. Successful completion of the trial could lead to a Biologics License Application for regulatory approval. BrainStorm plans to update investors on the NurOwn Phase 3 clinical program in Q4 2024.
Partners
growth-positive
BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing
BrainStorm Cell Therapeutics Inc. has signed a Memorandum of Understanding (MOU) with Pluri Inc. to manufacture NurOwn® for its planned Phase 3b trial in amyotrophic lateral sclerosis (ALS). This partnership allows BrainStorm to transfer its manufacturing technology to Pluris facility in Israel, enhancing its capacity to meet clinical supply requirements. The collaboration aims to support the potential future commercial distribution of NurOwn, pending regulatory approval. Pluri, known for its GMP-compliant manufacturing, will provide the necessary infrastructure to support BrainStorms clinical trials. This agreement aligns with BrainStorms strategic priorities as it advances its Phase 3b trial, marking a significant step towards potential regulatory approval of NurOwn.
Partners
growth-positive
Pluri Collaborates with Bar-Ilan University to Advance Cancer Immunotherapy for Solid Tumors, Supported by Israel Innovation Authority
Pluri Inc., a biotechnology company, has announced a collaboration with Bar-Ilan University Research and Development Company Ltd. (BIRAD), funded by the Israel Innovation Authority. This partnership aims to advance the development of Placental Mucosal Associated Invariant T (MAIT) cells for treating solid tumors. MAIT cells offer unique advantages over conventional T-cells, particularly in targeting solid tumors, a significant unmet medical need. The collaboration will integrate Prof. Cyrille Cohens Siglec-based Chimeric Switch Receptors into Pluris CAR-MAIT cell therapy platform to enhance efficacy and specificity. The funding will support the collaboration for a year, with an option for an additional year, focusing on preclinical studies. Pluris proprietary technology enables the expansion of immune cells from human placentas, offering potential breakthroughs in cancer immunotherapy.
Partners
growth-positive
Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing
Investor Summit Group, an organization focused on networking opportunities for the MicroCap and SmallCap community, announced that presentations from the August 20 Microcap Investor Summit Virtual 2024 Conference are now available for on-demand viewing. The event, which connects high-quality investors with valuable microcap and smallcap companies, offers a platform for attendees to engage with company management, ask questions to experts, and network with buy-side analysts. The presentations can be accessed through the Investor Summit Group website.
growth-positive
Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing
The Investor Summit Group has announced that presentations from the August 20 Microcap Investor Summit Virtual 2024 Conference are now available for on-demand viewing. The event, which focuses on creating networking opportunities for the microcap and smallcap community, allows participants to access valuable insights and information shared by industry experts. The Investor Summit Group aims to connect high-quality investors with promising microcap and smallcap companies through invite-exclusive events that feature companies with strong fundamentals and growth potential.
growth-positive
Pluri’s CDMO Selected to Manufacture Kadimastem’s Novel Cell Therapy Product Candidates
Biotechnology company Pluri Inc. has announced a tech transfer and manufacturing agreement with Kadimastem Ltd., a clinical stage biotechnology company. PluriCDMO™, Pluri’s contract development and manufacturing organization, will manufacture two cell therapy product candidates for Kadimastem. The collaboration is expected to enhance Kadimastems capacity to manufacture their products under good manufacturing practice conditions, and is integral to their strategy as they prepare for clinical trials and expand into the U.S. market.
Partners
growth-positive
Pluri Announces €1 Million Proof of Concept Agreement to Enhance Global Sustainable Vegetable Supply
Biotechnology company Pluri Inc. has announced a strategic proof of concept agreement with a leading international agriculture corporation. The collaboration aims to increase the global availability of vegetables, streamline supply chains, and promote sustainable agriculture. Pluris proprietary 3D cell expansion technology will be used to create a more agronomic and environmentally friendly infrastructure. The global vegetable farming market, currently valued at $1.3 trillion, is expected to reach $1.6 trillion by 2029.
PartnersExpand
growth-positive
Pluri Subsidiary Ever After Foods Secured $10 Million Strategic Investment to Solve Cultivated Food Scalability Challenges
Biotechnology company Pluri Inc. has announced strategic investments in its subsidiary, Ever After Foods Ltd., which offers a technology platform to produce cultivated food. The $10 million funding round, led by U.S. and EU strategic investors, will accelerate growth and enable efficient cultivated meat, fish, and seafood production at a global scale. Ever After Foods, a joint venture with Israeli food giant Tnuva Food-Tech Incubator, has exclusive licensing rights to use Pluri’s technology and intellectual property to develop, manufacture, and commercialize cultivated meat. The new investment will expand the reach and impact of its technology in the food industry.
InvestmentPartners
growth-positive
U.S. National Institutes of Health Exercises Option to Fund $1.4 Million 2nd Year Budget for Pluri’s PLX-R18 Acute Radiation Syndrome Contract
Biotechnology company Pluri Inc. has announced that the U.S. National Institute of Allergy and Infectious Diseases (NIAID) has exercised its option for the second year of a three-year $4.2 million contract. The contract funds the manufacturing and studies of Pluris cell therapy PLX-R18, a treatment for ionizing radiation injuries. The work during the contract period is expected to progress towards marketing approval for PLX-R18 as a medical countermeasure for exposure to radiation. The therapy could potentially be procured by the U.S. Strategic National Stockpile following FDA approval.
InvestmentPartners
growth-positive
Novel Medical Food Solution for the Elderly: Pluri & Wilk Collaborate to Develop Human Breast Milk-Derived Food Production on a Commercial Scale
Biotechnology company Pluri Inc. has announced a strategic collaboration with Wilk Technologies Ltd., a developer of authentic, cell-cultured human and animal milk components. The collaboration will leverage Pluri’s 3D cell expansion technology and Wilk’s expertise in developing cultured human breast and animal milk products to develop a unique medical food for the elderly. The global elderly nutrition market is valued at $25.2 billion and is estimated to reach $39.7 billion in less than 10 years. The collaboration aims to develop and scale Wilk’s innovative products to commercial readiness.
Partners
Growth-Positive
Pluri Third Quarter 2024 Earnings: US$1.01 loss per share (vs US$1.53 loss in 3Q 2023)
Pluri (NASDAQ:PLUR) has reported its third quarter 2024 results, revealing a net loss of US$5.29m, which is a 31% improvement from the same period in 2023. The loss per share also improved, from US$1.53 in 3Q 2023 to US$1.01 in 3Q 2024. Despite the net loss, Pluris shares have increased by 1.1% from a week ago. However, there are four warning signs that potential investors should be aware of before investing in Pluri.
growth-positive
Unleashing the Power of MAIT Cells: Pluri Launches Novel Immunotherapy Platform for Solid Tumor Cancer Treatment
Biotechnology company Pluri Inc. has launched its placental allogeneic MAIT cell platform for immunotherapy treatment for solid tumors. The company has developed a novel method for the expansion of immune cells and believes that its newly announced platform can revolutionize solid tumor treatment. The global cancer immunotherapy market is expected to reach $275.11 billion by 2032. In support of the development of its platform, leading cancer researchers Dr. Prasad S. Adusumilli and Dr. Richard L. Kendall have joined Pluri’s Scientific Advisory Board.
InvestmentManagement ChangesExpand
growth-positive
Breakthrough in Immune Cell Expansion: Pluri Granted U.S Patent for New Method
Biotechnology company Pluri Inc. has been granted a new U.S. patent for a novel method of expanding immune cells. The technology mimics the natural lymph node environment within the human body, allowing for efficient expansion of immune cells at scale and quality. This marks a significant advancement in the field of allogeneic cell therapy and positions Pluri at the forefront of innovation. The patented technology addresses the global immune cell engineering market, which is expected to reach $11.66 billion by 2030.
InvestmentExpand
growth-positive
Pluri’s Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming Conferences
Biotechnology company Pluri Inc. has announced that its leadership will be presenting at several upcoming conferences. These include the MIW, Germany-Israel Technology conference, the ATiO Conference 2024, Biomed Israel, and the Bio International Convention. The company will discuss its cell-based coffee business, its cell therapy product PLX-PAD, and its recently launched PluriCDMO service. Pluri Inc. is known for its 3D cell expansion technology which it uses to create cell-based solutions for various industries.
Management ChangesExpand
growth-neutral
Pluri Inc. Announces 1-for-8 Reverse Share Split
Biotechnology company Pluri Inc. has announced a reverse share split of its issued and outstanding common shares at a ratio of 1-for-8, to be implemented on April 1, 2024. The companys common shares will begin trading on the Nasdaq Capital Market on a post-split basis under the existing trading symbol PLUR. The reverse split will reduce the companys 41,816,959 common shares to approximately 5,227,120. The authorized capital shares of the company are also being reduced from 300,000,000 to 37,500,000. The reverse split will not impact any shareholders percentage ownership of Pluri or voting power.
Public Trading
growth-positive
Pluri’s Sustainable Cell-Based Coffee Addresses Critical Challenges Revealed in International Coffee Organization Market Report
Biotechnology company Pluri Inc. has addressed the coffee industrys price volatility challenge, as highlighted in the International Coffee Organization’s 2024 Market Report. The report cites erratic weather conditions as a factor in price instability. Pluris cell-based coffee aims to reduce this instability by moving coffee production into the lab, thus eliminating the effect of climate change and adverse weather conditions. The companys cell production method is environmentally sustainable, cost-effective, and highly scalable. Pluris CEO and President Yaky Yanay stated that their solution can help the industry produce coffee in a stable and controlled environment, ensuring consistent availability and price stability.
CustomersExpand
growth-positive
Engage with Pluri's Talent: Exciting Conference Appearances Ahead
Biotechnology company Pluri Inc. has announced its participation in several upcoming conferences, including Bio-Europe Spring, Advanced Therapies 2024, and the CISH Impact Investments Holdings Conference. Representatives from the company, including the Chief Business Development Officer-Pharma, Chief Technology Officer, Chief Commercial Officer, and Chief Executive Officer & President, will be attending these events. Pluri Inc. is known for its patented and validated state-of-the-art 3D cell expansion system, which is used to create cell-based products for commercial use. The company operates in the fields of regenerative medicine, food-tech, and agtech.
Partners
Pluri Selected as CDMO by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturing
growth-positive
Pluri™ Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivation
Pluri Inc., a leader in the agtech industry, has announced a significant expansion to its intellectual property portfolio with a new patent approval. The patent, titled A System for 3D Cultivation of Plant Cells and Methods of Use, represents a major breakthrough in Pluris proprietary 3D bioreactor technology. This technology enables efficient cultivation of plant cells across various applications, including sustainable agriculture and healthcare solutions. An immediate application for the patent is PluriAgtech’s sustainable cell-based coffee, which uses 98% less water and 95% less growing area. The global cellular agriculture market, valued at $133 billion in 2021, is projected to grow to $515 billion by 2030, positioning Pluris newly patented technology as a potentially transformative force within this industry.
InvestmentExpand
growth-positive
Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board
Biotech company Pluri Inc. has announced the appointment of James Roosevelt Jr. to its Advisory Board. Roosevelt, a former CEO of Tufts Health Plan and a public-service veteran, will contribute to Pluris strategic growth plans, particularly in the area of regenerative medicine. He will advise on longevity opportunities, best practices for securing and maintaining ongoing grants and contracts with U.S. government agencies, and facilitating relationships with investors and partners. Pluri is a leading company that transforms cells into solutions promoting global wellbeing and sustainability.
Management Changes
growth-positive
Pluri’s Innovation Across Various Industries: CEO Updates on Recent Achievements & 2024 Goals
Biotechnology company Pluri Inc. has announced a series of new products, services, collaborations, and partnerships through its various divisions. These include a new cell-based coffee business, an agtech division, a Contract Development and Manufacturing Organization division, and a $4.2 million contract with the U.S. NIH. The company has also partnered with Bar-Ilan University. Pluris CEO, Yaky Yanay, stated that the company has entered 2024 with significant momentum in every area of its business.
CustomersPartnersInvestmentExpand
growth-positive
Pluri Second Quarter 2024 Earnings: US$0.12 loss per share (vs US$0.24 loss in 2Q 2023)
Pluri has released its second quarter results for 2024, showing a net loss of US$4.91m, which is a 40% improvement from the same period in 2023. The loss per share also improved, from US$0.24 in 2Q 2023 to US$0.12 in 2Q 2024. Despite these losses, Pluris shares have increased by 2.7% from a week ago. However, the company is showing 4 warning signs in its investment analysis.
Public Trading
growth-positive
Israeli co Pluri launches cell-based coffee
Israeli biotech company Pluri has launched its cell-based coffee business activity, aiming to meet the growing global demand for sustainable, high-quality coffee at mass scale production. The companys cell-based coffee product, developed under its new business vertical PluriAgtech, is estimated to cut water usage by 98% compared to traditional methods of coffee production. Pluri plans to spin out its cell-based coffee as a new subsidiary led by Michal Ogolnik, focusing on developing innovative products, technologies and intellectual property for the coffee industry.
Expand
growth-positive
Step into the Future: Pluri Launches Sustainable Cell-Based Coffee as Countermeasure for Global Coffee Crisis
Biotech company Pluri Inc. has announced the launch of its cell-based coffee business activity, which aims to revolutionize the traditional coffee industry. The companys cell-based coffee product is designed to meet the growing global demand for sustainable, high-quality coffee at mass scale production. Pluris cell-based coffee is estimated to reduce water usage by 98% and reduce growing areas by 95%, thus reducing the carbon footprint. The company plans to spin out its cell-based coffee as a new subsidiary led by Michal Ogolnik.
Expand
growth-positive
Pluri Launches Advanced Global Cell Therapy Contract Development and Manufacturing Organization
Biotech company Pluri Inc. has launched a new business division, PluriCDMO™, to offer cell therapy manufacturing services. The division will provide support from preclinical and development stages to late-stage clinical and commercial production. The move is expected to generate new revenue for Pluri and help companies in the rapidly growing $5.2 billion cell and gene therapy sector. The division will be headed by Andy Lewin, an experienced CDMO executive. Pluris CEO and President Yaky Yanay stated that the launch of the CDMO division is a strategic move expected to boost revenues and cash flow.
CustomersPartnersExpand
growth-positive
Pluri and Bar-Ilan University to Develop PLX Cells for the Treatment of Cocaine Addiction
Biotech company Pluri Inc. has signed an agreement with BIRAD–Research & Development Company Ltd., the commercial arm of Bar-Ilan University, to develop Pluri’s PLX cells in the treatment of cocaine addiction. The agreement comes after positive pre-clinical data showed a one-time treatment with PLX-PAD significantly increased neurogenesis, offering an immediate, long-term therapeutic effect in treating cocaine addiction. Under the agreement, BIRAD will receive the right to further develop and commercialize PLX cells as a cocaine anti-addiction product, and Pluri is entitled to 20% revenue sharing from future sales of the product for anti-addiction.
Partners
Growth-Negative
Pluri Full Year 2023 Earnings: US$0.77 loss per share (vs US$1.28 loss in FY 2022)
Pluri has announced its full year 2023 results, with a net loss of US$28.3m, which is a 31% improvement from FY 2022. The loss per share also improved from US$1.28 in FY 2022 to US$0.77 in FY 2023. Despite these improvements, Pluris shares are down by 3.1% from a week ago. The article also mentions the need to consider investment risk, identifying 5 warning signs with Pluri.
Investment
growth-positive
Pluri’s PLX-R18 Increases Blood Cell Counts and Reduces Need for Transfusions in a Phase I Study: Results Published in Nature Bone Marrow Transplantation
Pluri Inc. has announced the publication of an article detailing the success of its cell therapy, PLX-R18, in a Phase I study. The study showed that PLX-R18 increased blood cell counts and reduced the need for blood transfusions in patients with incomplete hematopoietic recovery post-hematopoietic cell transplantation. PLX-R18, a placental-derived cell therapy, has been granted Orphan Drug Designation by the FDA. The results support the development of PLX-R18 for hematologic acute radiation syndrome (H-ARS). Pluri Inc. is a leading biotech company that transforms cells into solutions for wellbeing and sustainability.
Investment
growth-positive
Pluri Announces Appointment of Entrepreneur Lorne Abony to Board of Directors
Biotech company Pluri Inc. has announced the appointment of Lorne Abony to its Board of Directors. Abony is a successful entrepreneur with experience in building and scaling multi-billion-dollar businesses. He has invested in over 20 cellular agriculture and cultivated food companies. His expertise will contribute to Pluris strategic growth plans by utilizing its cell-expansion technology platform across various sectors. Pluri Inc. is a leading company that transforms cells into solutions promoting wellbeing and sustainability. The company operates in the field of regenerative medicine, food-tech, and biologics.
Management Changes
growth-positive
Deutsche Bank Predicts up to 160% Rally for These 3 Stocks — Here’s Why They Have Solid Upside
Deutsche Bank has released its quarterly Fresh Money List, which includes its top stock picks for the coming year. The list includes SeaWorld Entertainment, Planet Labs, and Warner Bros. Discovery. SeaWorld reported a Q1 record revenue of $293.3 million, an 8.4% year-over-year growth. Planet Labs, which operates a fleet of 200 Earth imaging satellites, reported a top line of $52.7 million in the first quarter of fiscal year 2024. Warner Bros. Discovery, a newly formed entity through the merger of TimeWarner and Discovery, Inc., reported revenues of $10.7 billion in its 1Q23.
InvestmentCustomers
growth-positive
U.S. National Institutes of Health to Fund $4.2 Million Contract to Advance Development of Pluri’s PLX-R18 in Conjunction with U.S. DoD as a Medical Countermeasure for Hematopoietic Acute Radiation Syndrome
Biotech firm Pluri Inc. has signed a three-year, $4.2M contract with the U.S. National Institute of Allergy and Infectious Diseases to further develop its cell therapy, PLX-R18, as a potential treatment for Hematopoietic Acute Radiation Syndrome (H-ARS), a deadly disease resulting from nuclear disasters and radiation exposure. The contract will support Pluris goal to achieve FDA approval for PLX-R18, which could qualify the product to be purchased for the U.S. Strategic National Stockpile as a medical countermeasure for exposure to radiation.
PartnersInvestment
Cell Manufacturing Pioneer, Pluri Inc., Unveils PluriMatrix: a Breakthrough System for Unprecedented Industrial Scale Production of Cell-Based Products
Israel’s Ministry of Labor Names Pluri as Winner of the 2022 Egalitarian Employment Award for its Commitment to Gender Diversity and Pay Equity
growth-positive
Israel's Ministry of Labor Names Pluri as Winner of the 2022 Egalitarian Employment Award for its Commitment to Gender Diversity and Pay Equity
Pluri Inc. has been selected as the winner of the 2022 Egalitarian Employment Award in the Large Company category by Israel’s Ministry of Labor, Social Affairs and Social Services. The award recognizes Pluris achievements in diversity, pay equity, and the promotion of women in its workforce. The companys CEO and President, Yaky Yanay, will accept the award at a ceremony in Jerusalem. Pluri will also receive a government grant of 40,000 NIS. Pluris management team issued a letter to employees and stakeholders expressing pride in the companys commitment to gender equality. Female employees represent an equal part of the companys workforce, including senior management and executive level positions. Pluri aims to inspire other companies to advance gender equality and empower women in the workplace.
CustomersPartners
Pluri CEO Issues Letter to Shareholders Summarizing the Strategy Change and Progress in 2022 and Announcing Food Tech Joint Venture Proof of Concept
Pluri Prices $8.2 million Private Placement Offerings Priced At-The-Market Under Nasdaq Rules
growth-positive
Pluri wins BioTech Breakthrough Cell Innovation of the Year Award
Pluri Inc., a leading biotechnology company, has won the Cell Innovation award in the Cell Biology category of the BioTech Breakthrough Awards. The company was recognized for its patented and validated 3D cell expansion system, which has applications in health, food, biologics, and more. Pluris technology platform allows for the cost-effective production of high-quality cells in large quantities, with consistency across different cell sources. The company operates a state-of-the-art manufacturing facility and has a portfolio of over 130 active patents. Pluri aims to establish partnerships to expand the impact of its technology to industries such as pharma, food-tech, and biologics. The article highlights the companys commitment to leveraging cell-based solutions for a better tomorrow.
PartnersExpand
Pluri wins BioTech Breakthrough Cell Innovation of the Year Award
growth-positive
Pluri to Present and Participate in Upcoming Conferences
Biotechnology company Pluri Inc. has announced its participation in three upcoming conferences. The companys Chief Commercial Officer and VP Business Development will attend CPHI Frankfurt, which brings together pharma industry participants from across the full supply chain. The Chief Financial Officer will attend the Jefferies London Healthcare Conference, the largest healthcare-dedicated conference in Europe. The Chief Medical Officer and Chief Technology Officer will participate in the virtual conference Challenges and Opportunities for Mesenchymal Stem Cells. The company is known for its patented and validated state-of-the-art 3D cell expansion system.
Expand
growth-positive
Pluri CEO Issues Letter to Shareholders Announcing New Tech Collaboration, Cost Reduction in line with New Strategy and Financial Updates
Biotechnology company Pluri Inc. has announced a new strategy that will reduce its cash burn by approximately 30%, leaving it with $56M in cash on its consolidated balance sheet. The company has also signed a technology collaboration agreement with a leading European manufacturer of active pharmaceutical ingredients (APIs) to use Pluri’s 3D cell expansion technology. This marks Pluri’s second tech collaboration, following a joint venture with Tnuva Group to develop cultivated food products. The company expects to generate revenues from this collaboration in the coming months.
PartnersExpand
€7.5 Million Granted to Collaborative PROTO Project led by Charité to Study Pluri’s PLX-PAD Cells for Osteoarthritis Treatment
growth-positive
Pluristem Therapeutics Inc. Changes its Name to "Pluri Inc." Reflecting the Companys Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional Industries
Pluri Inc., a leading biotechnology company, has announced a name change from Pluristem Therapeutics Inc. The company will now trade under the ticker symbol PLUR on Nasdaq. The name change reflects Pluris broader strategy of leveraging its 3D cell expansion technology to develop innovative cell-based products for various fields beyond medicine, including food-tech, agri-tech, and biologics. Pluris CEO and President, Yaky Yanay, believes that their technology offers quality, precision, efficiency, scalability, cost-effectiveness, and consistency. The companys first collaboration using its 3D cell-based technology was formed with Israeli food giant Tnuva Group to produce sustainable cultured food. Pluri aims to create next-generation cell-based products that improve human wellbeing, increase environmental sustainability, and address global challenges. The companys website has also been updated to reflect the name change.
Expand
growth-positive
"למען עתיד טוב יותר": האם זאת המהפכה הבאה בתחום המזון?
Israeli biotech company Pluristem has developed a unique platform for cell production and multiplication, which is used to develop innovative drugs and cultured food ingredients. The company recently announced a partnership with Tnuva, Israels largest food group, to establish a platform for the development, production, and marketing of cultured food. The joint company will develop components for the cultured meat market, with the potential to expand the partnership to the milk and fish sectors. Pluristems technology has been used to successfully multiply placental cells for 15 years and has the potential to be used in other sectors outside of pharma to produce a variety of innovative cell-based products.
PartnersExpand
growth-positive
Biotechnology Company Pluristem, and Israel's Largest Food Producer Tnuva, Launch Landmark Collaboration to Establish Cultured Food Platform
Pluristem Therapeutics Inc. and Tnuva Group have announced a collaboration to develop, manufacture, and commercialize cultured cell-based products for the food industry. Tnuva Group will invest $7.5 million in the new company formed for this collaboration, with the option to invest an additional $7.5 million. The collaboration aims to revolutionize the cultured food industry and develop alternative proteins. Pluristem has the capacity to design, develop, and manufacture cells for commercial use. The collaboration may expand to include cultured dairy and cultured fish products. The collaboration aligns with Pluristems strategy of leveraging its cell-based technology platform in key partnerships. The estimated market size for alternative meat is $140 billion by 2030. The collaboration is the first step for Pluristem to expand its business to verticals that require superior cell expansion proprietary technologies.
PartnersInvestment
growth-negative
Pluristem Reports Topline Results from its Phase II Studies of Acute Respiratory Distress Syndrome Associated with COVID-19
Pluristem Therapeutics announced topline results from its Phase II studies evaluating the safety and efficacy of PLX-PAD cells for the treatment of Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19. The studies did not meet the primary efficacy endpoint of statistically significant improvement in ventilator free days (VFD) at 28 days. However, a single administration of 300 million PLX-PAD cells showed overall better results compared to other treatment groups, with increased survival rates and VFD at day 60. Pluristem intends to explore opportunities based on the efficacy trends obtained from the studies. The company thanked everyone involved in the studies for their efforts.
Customers
growth-positive
Pluristem Completes Enrollment of Its Multinational Phase III Study of Muscle Regeneration Following Hip Fracture Surgery
Pluristem Therapeutics has fully enrolled its multinational Phase III clinical trial for the treatment of muscle injury following hip fracture. The study includes 240 patients from the U.S., Europe, and Israel, and topline results are expected in Q3 2022. The companys PLX-PAD cells, which secrete proteins to induce tissue healing, have shown promising results in a Phase I/II trial for muscle regeneration. If approved, PLX-PAD would be an innovative treatment for muscle regeneration. The company aims to improve the standard of care for patients recovering from hip fractures and potentially expand the use of cell-based therapy for other musculoskeletal indications. The estimated annual costs of care for hip fracture patients in the U.S. are between $10.3 billion and $15.2 billion.
Customers
growth-positive
Pluristem to Receive €20M Non-Dilutive Funding from the European Investment Bank
Pluristem Therapeutics Inc. has received a disbursement offer of €20 million from the European Investment Bank (EIB) as part of a €50 million non-dilutive financing agreement. This funding will support research and development in the European Union to advance Pluristems regenerative cell therapy platform. The first tranche of €20 million will be payable to the EIB in a single payment five years after the disbursement. Pluristems CEO and President, Yaky Yanay, expressed gratitude for the EIBs support and confidence in their technology. With this funding, Pluristem aims to strengthen the development of their product candidates. Pluristem has a strong cash balance of over $90 million following the receipt of the first tranche.
Investment
growth-positive
Pluristem Therapeutics Inc. Announces $30 Million Registered Direct Offering
Pluristem Therapeutics Inc. has entered into definitive agreements with institutional investors for the purchase and sale of 4,761,905 shares of its common stock at a purchase price of $6.30 per share in a registered direct offering, for gross proceeds of $30 million. The closing of the offering is expected to occur on or about February 4, 2021.
Investment
growth-positive
פרופ' גליה רהב תצטרף לוועדת המומחים לקורונה שמקימה פלוריסטם
Israeli biotech company Pluristem is establishing an advisory committee for its clinical program related to the treatment of COVID-19 patients suffering from Acute Respiratory Distress Syndrome (ARDS). The company is currently conducting a Phase II clinical trial of its PLX-PAD cells, derived from human placenta, for the treatment of severe cases of COVID-19 with ARDS in the US, Europe, and Israel. The advisory committee, chaired by Prof. R. Phillip Dellinger, consists of five prominent professors and doctors in the fields of infectious diseases, intensive care, pulmonary care, and internal medicine.
Management Changes
growth-positive
https://www.jpost.com/health-science/pluristem-to-enroll-participants-for-gvhd-treatment-at-sourasky-645845
Israeli biotech company Pluristem has received clearance to enroll patients for its Phase I/II study on the treatment of steroid-refractory chronic graft vs. host disease (GvHD). The study aims to investigate the effectiveness of PLX-PAD cells in treating the condition. Interim results from Cohort I showed no negative side effects and positive responses in patients. Pluristem is committed to enhancing the current treatment options for cGvHD patients. The company is collaborating with Prof. Ron Ram and Tel Aviv Sourasky Medical Center for the study.
Customers
growth-positive
Pluristem Expands its Phase II COVID-19 European Clinical Trial to Israel
Pluristem Therapeutics Inc. has received approval from the Israeli Ministry of Health to commence patient enrollment in Israel for the Company’s COVID-19 Phase II clinical trial. The trial will enroll 40 patients hospitalized with severe COVID-19 complicated by Acute Respiratory Distress Syndrome (ARDS) at clinical sites in Israel and Germany. The trial is in addition to Pluristem’s other COVID-19 clinical programs, including a Phase II study and an Expanded Access Program in the U.S., both under the U.S. Food and Drug Administration’s (FDA) approved protocol, and a per-patient compassionate use program in Israel.
CustomersExpand
growth-positive
Abu Dhabi Stem Cells Center and Pluristem Unveil Joint Projects at Malta Conferences Foundation Online Event
Pluristem Therapeutics Inc. and the Abu Dhabi Stem Cells Center (ADSCC) have unveiled their first joint projects in a presentation at the Malta Conferences Foundation. The projects are part of a recently signed Memorandum of Understanding (MOU) aimed at harnessing the power of regenerative medicine. The first joint project focuses on developing a potential COVID-19 treatment using Pluristems PLX cells administered via a nebulizer. ADSCC has reported success in using nebulizers to treat COVID-19 patients with stem cells sourced from the patients own blood. The collaboration will allow ADSCC to expand its stem cell therapy options and enable Pluristem to develop a new treatment delivery model. Additional projects, including collaboration in chronic Graft Versus Host Disease (cGvHD), are being discussed. The partnership between Pluristem and ADSCC is seen as a movement between Israel and the UAE, with the potential for future collaborations.
PartnersCustomers
growth-positive
Pluristem Launches FDA-Cleared COVID-19 Expanded Access Program, Enabling Patient Treatment Outside of Clinical Trial
Pluristem Therapeutics has received clearance from the FDA for its Expanded Access Program (EAP) to use its PLX-PAD cells in the treatment of Acute Respiratory Distress Syndrome (ARDS) caused by COVID-19. The EAP will allow up to 100 patients who are not eligible for the Phase II clinical trial to receive treatment with PLX-PAD cells. Pluristem will collect and evaluate data from the EAP alongside its clinical trial. The company is committed to delivering its PLX cells to meet the urgent medical need for new therapeutic options for critically ill COVID-19 patients. Pluristem is also conducting Phase II clinical trials in the US and Europe and treating patients under a compassionate use program in Israel.
Customers
growth-positive
Israeli-based Pluristem and Abu Dhabi Stem Cells Center sign deal to collaborate in development of cell therapies
Pluristem Therapeutics Inc., a regenerative medicine company, has signed a non-binding Memorandum of Understanding (MOU) with the Abu Dhabi Stem Cells Center (ADSCC) in the United Arab Emirates (UAE). The collaboration aims to advance the treatment and research of cell therapies for various medical conditions, including COVID-19. The partnership will involve exchanging research results, sharing samples, and utilizing equipment and testing. Pluristem has treated patients with its placental PLX-PAD allogeneic product, while ADSCC has been treating COVID-19 patients with stem cells sourced from the patients blood. The financial relationship between Israel and the UAE has been ongoing for years, with approximately 200 Israeli companies already exporting products to the UAE.
Partners
growth-positive
Pluristem Expands its COVID-19 Program to Europe, Receives PEI Clearance to Commence Phase II Study in Germany
Pluristem Therapeutics has received clearance from Germanys health regulatory agency to conduct a Phase II clinical trial for its PLX PAD treatment for severe COVID-19 cases. The trial will enroll 40 patients and evaluate the efficacy and safety of intramuscular injections of PLX PAD. The primary efficacy endpoint is the number of ventilator-free days during the 28-day study period. Pluristem is also conducting a Phase II trial in the US with 140 patients. PLX cells have immunomodulatory properties that may prevent or reverse the overactivation of the immune system in COVID-19 patients. The companys PLX cells have shown therapeutic benefit in animal studies and have the potential to mitigate the tissue-damaging effects of COVID-19.
CustomersInvestment
growth-positive
Pluristem Joins Forces with CRISPR-IL National Consortium to Advance Development of Cutting-Edge Genome Editing Solutions for Life Science Products
Pluristem Therapeutics has been selected as a member of the CRISPR-IL consortium, a group funded by the Israeli Innovation Authority. The consortium aims to develop artificial intelligence (AI) based end-to-end genome-editing solutions for human, plant, and animal DNA. Pluristems Vice President Research & Intellectual Property will lead the consortiums pharma working group. The CRISPR-IL consortium is funded with a total budget of NIS36 million (approximately US$10 million) and includes leading companies, medical institutions, and academic institutions. Pluristem plans to integrate CRISPR technology with its PLX platform to provide an expanded pipeline of products. The collaboration is expected to have a positive impact on the growth of Pluristem Therapeutics.
PartnersInvestment
growth-positive
Pluristem Provides 28-Day Follow Up for Ventilator-Dependent COVID-19 Patients under Compassionate Use Program in Israel and U.S.
Pluristem Therapeutics has provided an update on the status of COVID-19 infected patients treated with PLX cells under a compassionate use program in Israel and the FDA Single Patient Expanded Access Program in the U.S. The update includes data on the survival rate, mechanical ventilation, and hospital discharge of patients treated with PLX cells. The company plans to initiate a Phase II clinical study in the U.S. and continue treating patients through its compassionate use and FDA Single Patient Expanded Access Programs. Pluristem believes that its PLX cells have the potential to reduce the severity of COVID-19 pneumonia and pneumonitis. The company will provide a final update on the compassionate use program and the FDA program once they are completed.
CustomersExpand
growth-positive
FDA Covid-19 trial nod boosts Pluristem
The FDA has cleared Pluristems application for a Phase II study of its PLX cells in the treatment of severe Covid-19 cases. Pluristems share price rose 16.49% in response to the announcement. The study will treat 140 adult patients suffering from respiratory failure and ARDS due to COVID-19. Pluristem has been treating patients through compassionate use programs and has filed a Clinical Trial Authorization in Europe. The company aims to deliver its PLX cells to improve survival in severe COVID-19 cases.
Customers
growth-positive
Pluristem prices $15m offering to fund Covid-19 treatment
Pluristem Therapeutics has entered into definitive agreements with two institutional investors for a registered direct offering, raising $15 million. The funds will be used for the companys Phase II study of PLX cell therapy in the treatment of complications arising from Covid-19, as well as other clinical trial activities and general corporate purposes. The offering is expected to close on or before May 7, 2020.
Investment
growth-positive
European Investment Bank To Provide Israel's Pluristem With $54M For COVID-19, Other Cell Therapies
The European Investment Bank (EIB) has signed a collaboration agreement with the Israel Innovation Authority to pursue investments in companies and initiatives focused on public health. As part of the agreement, the EIB will support Israeli biomed company Pluristem Therapeutics with a venture debt loan of €50 million ($54 million). Pluristem develops placenta-derived cell therapy, including a potential treatment for COVID-19 patients. The financing will enable Pluristem to pursue research and development in the EU and advance its clinical work. The deal is the first Israeli-European project guaranteed by the European Fund for Strategic Investments.
Investment
growth-positive
https://www.jpost.com/health-science/israels-company-uses-placenta-cells-to-treat-critical-covid-19-patients-622960
Pluristem Therapeutics has treated its first three coronavirus patients in Israel with its placenta-based cell-therapy product. The company dosed three patients in two different hospitals in Israel under a compassionate-use program for the treatment of COVID-19. Pluristem expects to enroll additional Israeli patients in the coming days. The company will share updates on clinical outcomes once significant data has been gathered. Pluristems PLX cells have immunomodulatory properties and could potentially reduce the fatal symptoms of pneumonia and pneumonitis. The company is in discussions with regulators in the United States and Europe to define its clinical strategy for COVID-19.
Customers
https://www.micbloggy.com/2020/03/16/breaking-isreali-company-discovers-cell-to-treat-coronavirus/?utm_source=rss&utm_medium=rss&utm_campaign=breaking-isreali-company-discovers-cell-to-treat-coronavirus
growth-positive
https://www.jpost.com/HEALTH-SCIENCE/Israeli-cell-therapy-demand-could-be-worth-2-billion-by-2023-616747
Israeli regenerative-medicine company Pluristem Therapeutics announced the results of a research study that found critical limb ischemia (CLI) has a significantly unmet need indication and constitutes a significant burden on the US healthcare system. The study validates the market potential for Pluristems PLX-PAD regenerative cell therapy, which is currently in a global Phase III study. The addressable market for PLX-PAD for Rutherford V CLI patients is expected to reach $2 billion by 2023. CLI patients, who are unsuitable for revascularization surgery, face high rates of death and amputation. Pluristems Phase III study aims to prevent amputation and improve the lives of CLI patients.
Customers
growth-positive
Positive results for radiation prophylaxis
Pluristem Therapeutics Inc. presented positive results from studies of its PLX-R18 cell therapy product as a potential prophylactic countermeasure against acute radiation syndrome. The studies showed a significant increase in survival rates and recovery of blood lineages in animals exposed to radiation. PLX-R18 has been granted an FDA Orphan Drug Designation and is being evaluated for the treatment of ARS by the National Institute of Allergy and Infectious Diseases. Pluristem is in discussions with the Biomedical Advanced Research and Development Authority for a study to demonstrate the superiority of PLX-R18. The company is also collaborating with the Department of Defense to study the treatment of long-term lung injuries. Pluristem aims to bring innovative treatments for bone marrow deficiency indications.
PartnersInvestment
growth-positive
Pluristem and U.S. Department of Defense Present Positive Data from Studies Testing PLX-R18 as a Prophylactic Treatment for Acute Radiation Syndrome
Pluristem Therapeutics presented positive results from studies of its PLX-R18 cell therapy product, which demonstrated a significant increase in survival rates and recovery of blood lineages in animals exposed to radiation. The studies were conducted by the U.S. Department of Defenses Armed Forces Radiobiology Research Institute. PLX-R18 was administered as a potential prophylactic countermeasure against acute radiation syndrome. The results showed a 74% survival rate in the treated group compared to 4% in the placebo group. The therapy also improved regenerative capability in all blood lineages. Pluristem aims to provide federal agencies access to PLX-R18 for both pre- and post-radiation exposure. The company is also conducting studies with the National Institute of Allergy and Infectious Diseases for the treatment of radiation exposure.
InvestmentPartners
growth-positive
Pluristem and U.S. Department of Defense to Announce Data from Studies Testing PLX-R18 as a Prophylactic Treatment for Acute Radiation Syndrome at RITN
Pluristem Therapeutics announced that results from studies of its PLX-R18 cell therapy product will be presented at the upcoming Radiation Injury Treatment Network Workshop. The studies, conducted by the U.S. Department of Defense, evaluated PLX-R18 as a potential prophylactic countermeasure against acute radiation syndrome. The data demonstrated increased survival rates and enhanced recovery in radiation subjects. PLX-R18 has also been granted an FDA orphan drug designation for the treatment of ARS. Pluristem Therapeutics is a leading regenerative medicine company developing placenta-based cell therapy products.
PartnersInvestment
growth-negative
Pluristem's new CEO seeks to recoup losses
Pluristem Therapeutics Ltd. has announced a change in management, with Yaky Yanay becoming the sole CEO. The company will implement cost-cutting measures, including a 25% cut in executive salaries, and will focus on products that are close to market. No layoffs are planned. Pluristem is currently focusing on three areas: critical limb ischemia trial, muscle regeneration trial, and a treatment for acute radiation syndrome. The company aims to reach an agreement with BARDA similar to the one it signed with MediWound. Pluristems share price has fallen by 54% over the past year. The companys market cap is currently $88 million.
Management Changes
growth-positive
Pluristem Completes Transition Period of Co-CEO Structure Yaky Yanay appointed as Chief Executive Officer and Zami Aberman appointed as Executive Chairman of the Board
Pluristem Therapeutics Inc. has announced the completion of the transition period of its Co-CEO structure and the appointment of Yaky Yanay as sole Chief Executive Officer and President. Zami Aberman has been appointed as Executive Chairman of the Board. The company is focused on developing novel placenta-based cell therapy products and is currently conducting late-stage clinical trials in several indications. Pluristem aims to become a global leader in the development, manufacture, and marketing of its cell-based therapeutics. The companys technology has the potential to save lives, improve quality of life, and have a positive impact on the global healthcare system. Pluristem has a strong intellectual property position, a GMP-certified manufacturing and research facility, and strategic relationships with major research institutions.
Management Changes
growth-positive
Pluristem Strengthens Its Manufacturing Competitive Advantage, Presents its First Proprietary Serum-Free Cell Therapy Product
Pluristem Therapeutics has developed a serum-free formulation to support the manufacturing of cell therapy products. This formulation allows for large-scale, highly consistent production with operational independency from third-party suppliers. The serum-free media formulation supports cell therapy production in both standard two-dimensional cell culture and a proprietary three-dimensional bioreactor-based cell culture platform. Pluristem believes that this achievement will increase their supply volume and reduce the risk of contaminants. The company is targeting marketing approval for its final pivotal studies and aims to elevate the standard of cell therapy production.
InvestmentExpand
growth-positive
Lead Physicians in Pluristem's Pivotal Study in Critical Limb Ischemia Publish Peer-Reviewed Paper
Pluristem Therapeutics has published a peer-reviewed article in the European Journal of Vascular and Endovascular Surgery, highlighting the design rationale and potential impact of its PLX-PAD cell therapy in the treatment of critical limb ischemia (CLI). The article discusses the ongoing Phase III study evaluating the therapy and its potential economic benefit. The study aims to provide a new treatment option for CLI patients who are not eligible for revascularization. The PLX-PAD cell therapy has shown positive results in previous Phase I and II studies, including pain reduction, improved tissue perfusion, and reduced surgical events. Pluristem aims to make this treatment available to CLI patients as quickly as possible. The company has completed enrollment of half of the studys population and may provide an interim analysis after a 12-month follow-up period.
CustomersInvestment
growth-positive
Pluristem Files Patent Application for the Use of its Advanced Manufacturing Technology in the Cannabis Industry
Pluristem Therapeutics has filed a provisional patent application for the use of its 3-D cell culturing technology in the manufacturing of cannabinoid-producing cells. The company aims to shift the cannabis industry from agriculture-based growing to a Good Manufacturing Practice (GMP) 3-D cell culturing platform, allowing for automated and controlled growth of cannabinoid-producing cells at larger scales. Pluristem believes that its advanced manufacturing platform gives it a competitive advantage in the cell therapy industry. While the company is focused on advancing its PLX cell therapy products, it sees the cannabis industry as an attractive opportunity to leverage its technology and manufacturing capabilities.
PartnersInvestment
growth-positive
Pluristem Completes Interim Enrollment in Pivotal CLI Study, Targeting Potential Conditional Marketing Approval in Europe
Pluristem Therapeutics has achieved a significant milestone in the development of its PLX-PAD cell therapy for the treatment of critical limb ischemia (CLI). The company has successfully enrolled over 50% of the patients in its Phase III pivotal study, allowing for an interim analysis of efficacy. If positive, this analysis could support an application for conditional marketing approval in Europe. Pluristem has also initiated its FDA-approved Expanded Access Program, which will enroll up to 100 patients with CLI. The company has received a €7.6 million grant from the European Unions Horizon 2020 program for its CLI program. Pluristems PLX-PAD has been granted FDA Fast Track Designation for CLI treatment.
InvestmentExpand
Pluristem Therapeutics Inc. Announces Pricing of Its Public Offering and Registered Direct Offering for Aggregate Proceeds of Approximately $20 Million
growth-positive
Pluristem Therapeutics Inc. Announces Proposed Public Offering of Common Stock and Warrants and Concurrent Registered Direct Offering of Common Stock
Pluristem Therapeutics Inc. plans to offer and sell shares of its common stock and warrants in an underwritten public offering and shares of its common stock in a concurrent registered direct offering. The company intends to use the net proceeds for research and product development activities, clinical trial activities, investment in capital equipment, and for working capital and other general corporate purposes. The offerings are subject to market and other conditions, and there is no assurance as to whether or when the offerings may be completed. Pluristem Therapeutics Inc. is a leading regenerative medicine company developing novel placenta-based cell therapy product candidates.
Public TradingInvestment
growth-positive
Pluristem Therapeutics Inc. Announces Pricing of Its Public Offering and Registered Direct Offering for Aggregate Proceeds of Approximately $20 Million
Pluristem Therapeutics Inc., a leading regenerative medicine company, has announced the pricing of an underwritten public offering of over 27 million shares of its common stock and warrants. The gross proceeds from the underwritten public offering and the concurrent registered direct offering are expected to be $20 million. The company intends to use the net proceeds of both offerings for research and product development activities, clinical trial activities, investment in capital equipment and for working capital and other general corporate purposes. The offerings are expected to close on or about April 8, 2019.
InvestmentPublic Trading
growth-positive
Pluristem Enters into Collaboration with NASA to Study PLX Therapeutic Benefits in Space Missions
Pluristem Therapeutics Inc. has announced a collaboration with NASAs Ames Research Center to evaluate the potential of its PLX cell therapies in preventing and treating medical conditions caused during space missions. The collaboration has been awarded the 2019 NASA Ames Research Innovation Award. The project aims to evaluate the potential of PLX cell therapies in addressing muscle and bone loss, as well as radiation exposure experienced by astronauts during space missions. Pluristem believes that this collaboration further demonstrates the broad clinical utility of its PLX cell therapies. The collaboration is expected to establish a mutually beneficial partnership between Pluristem and NASA.
Partners
growth-positive
Pluristem to Collaborate with Israeli Ministry of Defense in the Treatment of Burn Injuries
Pluristem Therapeutics has received a joint grant from the Israeli Ministry of Defense and the Israel Innovation Authority for the development of its PLX cells for the treatment of burn injuries. The grant will support studies on the effects of PLX cells in expediting burn wound healing. Pluristem has previously demonstrated the positive impact of its technology in various indications. The company will collaborate with professionals specializing in burn injuries from Israeli hospitals and the Israeli Defense Forces medical corps.
Partners
growth-positive
Stem cell co Pluristem awarded $8.7m EU grant
Pluristem Therapeutics has been awarded an $8.7 million grant from the EU R&D Horizon 2020 program for its Phase III study of PLX-PAD cells to support recovery following surgery for femoral neck fracture. This grant reflects a vote of confidence by the EU and signals the need for cell therapy solutions. The Phase III trial will be a collaborative effort between Pluristem and an international consortium led by the Charité - Universitätsmedizin Berlin. If successful, the trial could improve outcomes in femoral neck fracture procedures and change the way recovery is managed worldwide. Pluristems PLX-PAD program has been accepted into Europes Adaptive Pathway program and plans to enroll patients at clinical sites throughout Europe and the US.
Investment
growth-positive
Chinese investor approves $30m Pluristem investment
Innovative Medical, a Chinese company, has approved a $30 million investment in Pluristem Therapeutics, an Israeli placenta-based cell therapy products developer. This investment makes Innovative Medical the largest shareholder in Pluristem. The investment was made at a 15% premium on the companys share price. Pluristems market cap is NIS 476 million, while Innovative has a market cap of $1.43 billion. Pluristem believes that the deal can open doors in China and enable it to find a marketing partner there.
Investment
growth-positive
Israeli stem cell co Pluristem receives $3.3m grant
Pluristem Therapeutics Ltd., through its unit Pluristem Ltd., has been awarded a NIS 12.7 million grant from the Ministry of Economy and Industrys Israel Innovation Authority. The grant will support clinical trials and R&D activities for the Haifa-based stem cell developer. The continued backing of the Israeli Innovation Authority is seen as a vote of confidence in Pluristems technology and strategy.
Investment
growth-positive
Pluristem raises $17m from private investors
Pluristem Therapeutics Ltd. has raised $17 million from private investors through a shelf prospectus. The companys market cap is NIS 700 million. This is Pluristems first offering since 2012 and they had $44 million in cash before the offering. The company did not specify how they will use the proceeds, but they have several clinical trials pending.
Investment
Growth-Positive
Pluristem Receives $2.9M Grant From OCS
Pluristem Therapeutics, an Israeli company that develops placenta-based therapy products, has been awarded a grant of NIS 11 million (approximately $2.9 million) from the Office of the Chief Scientist. The grant will be used for research and development in 2015. The company was founded in 2001 by Shai Meretzki.
Investment
growth-positive
Recent Scientific Discoveries about the Human Placenta May Reflect Well on Placenta-Based Cell Therapies
Pluristem Therapeutics is a key player in the regenerative medicine space, using cells from donated human placentas to develop therapeutic cells. The company is involved in the Human Placenta Project, which aims to improve understanding of the placenta and its role in human health and development. Pluristems therapeutic cells have the potential to treat cardiovascular diseases, muscle and tendon injuries, and preeclampsia. The company is planning Phase II and Phase III trials in cardiovascular and muscle injury indications, as well as a Phase I study in preeclampsia. Pluristem recognizes the importance of the placenta as a source of therapeutic cells and is pleased to contribute to scientific knowledge and advancements in this field.
InvestmentExpand
Pluri Team
Employee Info
| Employees (range) | 201-500 |
| Exact count | 258 |
| Team members | 7 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 12 classification IDs that could be used for matching.
Pluri Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 100/100 |
| Missing | markets |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 513371666 |
| Crunchbase | pluristem-therapeutics |
| Phone | +972747108600 |
| Creator | Rebecca Mack |
| Creator email | rebeccamack26@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2023-08-01T00:00:00.000Z |
| Created | 2014-07-29T00:00:00.000Z |
| Claimed | Yes |
| Status detail | Public on NASDAQ on Apr, 2003;Public on TASE on Dec, 2010; |